Skip to main content

Security report for taro.ca

Taro Pharmaceutical Industries Ltd. · Healthcare · Canada

Medium risk. 11 critical or high findings in Security headers, GDPR outside view and 2 other checks.

Security score

57/100

Risk levelMedium

0–100, higher is better. How it is calculated

Taro Pharmaceutical Industries Ltd. is a Canadian pharmaceutical company specializing in the development, manufacturing, and marketing of affordable prescription and over-the-counter medications. It operates as a subsidiary of Sun Pharma, a global healthcare company. The website serves healthcare professionals and consumers with product information, resources, and customer service. The company has a strong market position in the generic pharmaceutical sector in Canada, supported by its parent company’s global presence. Technically, the website is built on Drupal 7 with a technology stack including jQuery and Bootstrap. It is mobile optimized and provides a good user experience with clear navigation and professional design. Google Analytics and Google Tag Manager are used for analytics and tracking. However, some technical debt is evident, such as the use of an outdated jQuery version and lack of DNSSEC, which could pose security risks. From a security perspective, the site uses HTTPS and has domain transfer protections but lacks DNSSEC and explicit security headers. No incident response or security policies are publicly documented. Privacy compliance is basic, with a privacy policy and terms of use present but no cookie consent mechanism or GDPR compliance indicators. Contact information is limited to a contact form without direct emails or phone numbers visible. Overall, the website is legitimate, professional, and trustworthy but could improve its security posture and privacy compliance to better protect users and align with modern standards.

Scanned

NIS2 and GDPR posture

GDPR outside view
53/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

11 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Policy found

      GDPR requires clear information about cookie usage

      What to do: Add a dedicated cookie policy explaining cookie usage and purposes

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  3. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

  4. DNS health

    DNS sends visitors and email to the right servers. Misconfigured records can cause outages or let someone redirect your traffic.

    • High

      Unregistered MX Record

      MX record points to unregistered domain: andas01.sunpharma.com

      What to do: Remove or fix MX record pointing to unregistered domain

      • RFC 5321 §5.1
      • NIS2 21(2)(i)
      • IR 2024/2690 12.4: Implementing Regulation (EU) 2024/2690, Annex point 12.4: Asset inventory
      • NIST CM-8: NIST SP 800-53 Rev. 5 CM-8: System Component Inventory

Need hands-on remediation? Email guard@offseq.com

Keep watching taro.ca

This scan found 30 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
67
Security headers
50
Email security
70
DNS health
0
Network security
100
GDPR outside view
53
Average
57

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Taro Pharmaceutical Industries Ltd. is positioned as a key player in the Canadian generic pharmaceutical market, leveraging its parent company Sun Pharma’s global footprint. The business model focuses on affordable medications for both prescription and OTC markets, targeting healthcare professionals and consumers. The company maintains a network of worldwide sites and partners, enhancing its market reach. The website content and structure support a professional image with product launches and news updates indicating active business operations. The absence of direct contact emails and phone numbers suggests a preference for controlled communication channels, likely for regulatory compliance. The company’s long domain history and consistent WHOIS data reinforce its credibility and stability in the pharmaceutical sector.

Security posture

The website demonstrates a moderate security maturity level. HTTPS is enforced, and the domain status includes clientTransferProhibited, which protects against unauthorized domain transfers. However, the absence of DNSSEC and security headers such as Content-Security-Policy and Strict-Transport-Security reduces the overall security robustness. The use of an outdated jQuery version introduces potential vulnerabilities. No public security or incident response policies are available, and no dedicated security contact channels are provided. Privacy compliance is minimal, lacking cookie consent mechanisms and GDPR indicators. These gaps present moderate risks, particularly in regulatory compliance and client data protection. Enhancing technical security controls and transparency around security policies would improve the security posture significantly.

Recommendations

  1. Enable DNSSEC on the domain to enhance DNS security and prevent spoofing.
  2. Update all JavaScript libraries, especially jQuery, to the latest secure versions to mitigate vulnerabilities.
  3. Implement and publish explicit security policies including incident response and vulnerability disclosure.
  4. Add security headers such as Content-Security-Policy, X-Frame-Options, and Strict-Transport-Security to improve browser security.
  5. Introduce a cookie consent mechanism to comply with privacy regulations and improve user trust.

Contact details published on the site

Addresses
Legal name
Taro Pharmaceutical Industries Ltd.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Taro Pharmaceutical Industries Ltd.
Description
Taro develops, manufactures and markets affordable prescription and over-the-counter medications. It is a privately held company wholly owned by Sun Pharma, a global healthcare company with innovative therapies, generic medicines and consumer healthcare products.
Key services
Prescription medications, Over-the-counter medications, Product resources and customer service
Content quality
good
Branding
consistent

Technology

Stack
jQuery 1.10.2, Bootstrap, Drupal 7, Google Analytics
Frameworks
Drupal 7
Performance
moderate
Mobile
good
Accessibility
good
SEO
good

Security

Observed score
65/100
Good practices seen
  • HTTPS enabled
  • ClientTransferProhibited domain status

Analytics and tracking

Services
Google Analytics, Google Tag Manager
Tracking level
moderate
Privacy practices
basic

Advertising

Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is a Drupal 7 based pharmaceutical company site with clear branding and product information.
  2. No WAF or blocking detected; content is fully accessible.
  3. Privacy policy and terms of use are present but cookie policy and explicit GDPR compliance are minimal.
  4. No direct contact emails or phone numbers found in the HTML; contact is via a form on a dedicated contact page.
  5. Use of outdated jQuery version may pose security risks.
  6. No DNSSEC enabled for domain; security headers not explicitly detected.
  7. Google Analytics and Google Tag Manager are used for tracking.
  8. Website is mobile optimized and accessible with good navigation and professional design.
  9. WHOIS data is consistent and supports legitimacy of the business.
Technical notes

Notes

The website is built on Drupal 7, a mature but aging CMS platform, using jQuery 1.10.2 and Bootstrap for frontend components. The site is mobile responsive and accessible, with good SEO practices including meta tags and structured navigation. Google Analytics and Google Tag Manager are integrated for user tracking. However, the use of outdated JavaScript libraries and lack of DNSSEC indicate technical debt and potential security risks. Performance is moderate, with no explicit indicators of slow loading but also no advanced optimization techniques detected. The hosting and domain registration are managed by CSC Corporate Domains, a reputable provider. Overall, the technical infrastructure supports business needs but would benefit from modernization and enhanced security controls.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with taro.ca. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review taro.ca.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.